Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02867384
Recruitment Status : Recruiting
First Posted : August 15, 2016
Last Update Posted : June 19, 2019
Sponsor:
Collaborator:
Roche-Genentech
Information provided by (Responsible Party):
Corey S. Cutler, MD, MPH, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2024